

Supplementary information for the article entitled Exploring the Therapeutic Potential of Spilanthol from *Acmella paniculata* (Wall ex DC.) R. K. Jansen in Attenuating Neurodegenerative Diseases: A Multi-Faceted Approach Integrating *In-Silico* and *In-Vitro* Methodologies

Sanith Sri Jayashan ^{1,2}, Nitchakan Darai ³, Thanyada Rungrotmongkol ^{4,5}, Peththa Wadu Dasuni Wasana⁶, San Yoon Nwe ^{1,2}, Wisuwat Thongphichai ^{1,2}, Gunasekaran Suriyakala ^{1,2}, Pasarapa Towiwat ^{7,8} and Suchada Sukrong ^{1,2*}

¹ Department of Pharmacognosy and Pharmaceutical Botany, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok 10330, Thailand

² Center of Excellence in DNA Barcoding of Thai Medicinal Plants, Chulalongkorn University, Bangkok 10330, Thailand

³ Futuristic Science Research Center, School of Science, Walailak University, Nakhon Si Thammarat, 80160, Thailand

⁴ Center of Excellence in Biocatalyst and Sustainable Biotechnology, Department of Biochemistry, Faculty of Science, Chulalongkorn University, Bangkok, Thailand

⁵ Program in Bioinformatics and Computational Biology, Graduate School, Chulalongkorn University, Bangkok, Thailand

⁶ Department of Pharmacy, Faculty of Allied Health Sciences, University of Ruhuna, Galle 80000, Sri Lanka

⁷ Department of Pharmacology and Physiology, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok 10330, Thailand

⁸ Animal Models of Chronic Inflammation-associated Diseases for Drug Discovery Research Unit, Chulalongkorn University, Bangkok 10330, Thailand

* Correspondence: Suchada.su@chula.ac.th, Tel.: (66)218-8363

Table S1. *In-Silico* ADMET Prediction of spilanthol using pkCSM

Properties	Model name (Unit)	Result
Absorption	Water solubility (log mol/L)	-4.374
	Caco2 permeability (log Papp in 10 ⁻⁶ cm/s)	1.368
	Intestinal absorption (human) (% absorbed)	92.81
	Skin Permeability (log Kp)	-1.923
	P-glycoprotein substrate	No
	P-glycoprotein I inhibitor	No
	P-glycoprotein II inhibitor	No
Distribution	VDss (human) (log L/kg)	0.096
	BBB permeability (log BB)	0.645
	CNS permeability (log PS)	-1.554
Metabolism	CYP2D6 substrate	No
	CYP3A4 substrate	No
	CYP2D6 inhibitor	No
	CYP3A4 inhibitor	No
Excretion	Total Clearance (log ml/min/kg)	0.583
	Renal OCT2 substrate	No

Table S2. Drug likeness prediction of spilanthol

Drug Likeness					
Lipinski	Ghose	Veber	Egan	Muegge	Bioavailability Score
Yes 0 violation	Yes	Yes	Yes	Yes	0.55




Figure S1. Bioavailability radar of the spilanthol

Table S3 *In-silico* Toxicity Prediction of Spilanthol using protox-II

Classification	Target	Prediction	Probability
Organ Toxicity	Hepatotoxicity	Inactive	0.86
Toxicity endpoint	Carcinogenicity	Inactive	0.61
	Immunotoxicity	Inactive	0.98
	Mutagenicity	Inactive	0.8
	Cytotoxicity	Inactive	0.75
Tox21-Nuclear receptor signalling pathways	Aryl hydrocarbon Receptor (AhR)	Inactive	0.97
	Androgen Receptor (AR)	Inactive	0.99
	Androgen Receptor Ligand Binding Domain (AR-LBD)	Inactive	0.99
	Aromatase	Inactive	0.98
	Estrogen Receptor Alpha (ER)	Inactive	0.93
	Estrogen Receptor Ligand Binding Domain (ER-LBD)	Inactive	0.99

	Peroxisome Proliferator Activated Receptor Gamma (PPAR-Gamma)	Inactive	0.99
Tox21-Stress response pathways	Nuclear factor (erythroid-derived 2)-like 2/antioxidant responsive element (nrf2/ARE)	Inactive	0.98
	Heat shock factor response element (HSE)	Inactive	0.98
	Mitochondrial Membrane Potential (MMP)	Inactive	0.97
	Phosphoprotein (Tumor Supressor) p53	Inactive	0.99
	ATPase family AAA domain-containing protein 5 (ATAD5)	Inactive	0.99




Figure S3. RMSD plots of all-atom residues for assessing structural stability and conformational changes in the molecular systems: IKK α and NF κ B1




Figure S4. ¹H-NMR (400 MHz, CDCl₃) spectrum of spilanthalol (ranging from 0.5 – 7.5)




Figure S5. ¹³C-NMR (125 MHz, CDCl₃) spectrum of spilanthal